|
시장보고서
상품코드
2064546
에타너셉트 시장 규모, 점유율, 성장 분석 : 제품 약물 유형별, 용도 임상 적응증별, 투여 경로별, 유통 채널별, 지역별 - 산업 예측(2026-2033년)Etanercept Market Size, Share, and Growth Analysis, By Product Drug Type, By Application Clinical Indication, By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 에타너셉트 시장 규모는 2024년에 174억 5,000만 달러로 평가되었으며, 2025년 181억 7,000만 달러에서 2033년까지 250억 5,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 4.1%로 성장할 것으로 전망됩니다.
전 세계 에타너셉트 시장은 TNF-α를 표적으로 삼아 류마티스 관절염, 건선, 강직성 척추염 등의 자가면역 질환 치료에 중점을 두고 있습니다. 그 중요성은 질환의 진행을 억제함으로써 신체 장애를 완화하고 의료비를 절감할 수 있다는 점에 있습니다. 이 시장은 재조합 단백질의 발견부터 성공적인 임상시험, 규제 당국의 승인, 그리고 유럽 및 신흥 시장에서 바이오시밀러의 부상에 힘입어 더욱 견고한 구조로 발전해 왔습니다. 바이오시밀러에 의한 경쟁과 신흥 지역에서의 지리적 범위 확대는 판매량 증가와 단위당 비용 절감의 주요 촉진요인이 되고 있습니다. 또한, 혁신적인 약물전달 시스템과 병용요법은 환자의 복약 순응도를 높이고 의료 시스템의 효율을 최적화하는 동시에 새로운 수익원을 창출하고 있습니다.
전 세계 에타너셉트 시장의 성장요인
전 세계 에타너셉트 시장의 주요 성장 요인 중 하나는 류마티스 관절염이나 건선과 같은 자가면역 질환의 유병률 증가입니다. 이러한 만성 질환의 유병률이 높아짐에 따라, 환자에게 장기적인 증상 완화와 삶의 질 향상을 가져다주는 효과적인 생물학적 제제에 대한 수요가 증가하고 있습니다. 또한, 의약품 개발의 진전과 에타너셉트의 적응증이 지속적으로 확대됨에 따라 치료 용도가 넓어지면서 매출을 더욱 끌어올리고 있습니다. 또한, 조기 치료의 이점에 대한 의료진과 환자의 인식이 높아지고 있는 점도 임상 현장에서 에타너셉트의 사용 확대에 기여하고 있습니다.
세계 에타너셉트 시장의 제약요인
세계 에타너셉트 시장에서 주요 시장 억제요인은 바이오시밀러의 보급 확대입니다. 에타너셉트의 특허 보호 기간이 만료됨에 따라 여러 바이오시밀러가 시장에 진입하고 있어, 경쟁 심화와 가격 하락에 대한 우려가 제기되고 있습니다. 이러한 변화는 비용을 중시하는 의료 제공자와 환자들이 보다 저렴한 대체품을 선택하도록 유도할 뿐만 아니라, 원료의약품 제조사들에게도 가격 전략의 정당성을 설명하도록 압력을 가하고 있습니다. 또한, 가치 기반 의료 및 보상 모델에 대한 중요성이 커지고 있는 점도 에타너셉트의 도입을 더욱 제한할 가능성이 있습니다. 이는 지불자들이 브랜드 의약품보다 저렴한 치료 옵션을 점점 더 선호하고 있기 때문입니다.
세계 에타너셉트 시장의 동향
전 세계 에타너셉트 시장에서는 개별 환자의 요구에 맞춘 약물 투여의 맞춤화를 중시하며, 환자 중심의 통합 치료로 뚜렷한 전환이 나타나고 있습니다. 이러한 추세는 투여 일정의 유연화, 지원 프로그램의 확충, 그리고 환자의 참여와 치료 순응도를 높이는 교육 활동으로 특징지어집니다. 치료 성과 전반을 우선시함으로써, 시장은 단순한 유효성을 넘어선 부가가치를 통해 차별화를 꾀하며, 환자에게 공감을 불러일으키는 종합적인 치료 경험에 초점을 맞추고 있습니다. 이러한 진전은 건강상의 성과를 향상시킬 뿐만 아니라, 더 강력한 브랜드 충성도를 형성함으로써, 이와 같은 지원 체계를 갖추지 못한 경쟁사들에 비해 에타너셉트를 유리한 입지에 놓이게 하고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 에타너셉트 시장 규모 : 제품 약물 유형별
세계의 에타너셉트 시장 규모 : 용도 임상 적응증별
세계의 에타너셉트 시장 규모 : 투여 경로별
세계의 에타너셉트 시장 규모 : 유통 채널별
세계의 에타너셉트 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.06.26Global Etanercept Market size was valued at USD 17.45 Billion in 2024 and is poised to grow from USD 18.17 Billion in 2025 to USD 25.05 Billion by 2033, growing at a CAGR of 4.1% during the forecast period (2026-2033).
The global etanercept market focuses on treating autoimmune disorders like rheumatoid arthritis, psoriasis, and ankylosing spondylitis by targeting TNFalpha. Its significance lies in its capacity to modify disease progression, thereby alleviating disability and reducing healthcare costs. The market has evolved from the discovery of recombinant proteins to a more robust landscape, bolstered by successful clinical studies, regulatory approvals, and the rise of biosimilars in Europe and emerging markets. The competition posed by biosimilars and the increasing geographical reach in emerging regions are pivotal drivers of volume growth and declining per-unit costs. Furthermore, innovative medication delivery systems and combination therapies enhance patient adherence, creating additional revenue streams while optimizing healthcare system efficiency.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Etanercept market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Etanercept Market Segments Analysis
Global etanercept market is segmented by product drug type, application clinical indication, route of administration, distribution channel and region. Based on product drug type, the market is segmented into Originator Biologics and Biosimilars. Based on application clinical indication, the market is segmented into Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis and Juvenile Idiopathic Arthritis. Based on route of administration, the market is segmented into Subcutaneous Injections and Intravenous Infusions. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Etanercept Market
One of the key market drivers for the global etanercept market is the increasing prevalence of autoimmune disorders, such as rheumatoid arthritis and psoriasis. As the incidence of these chronic conditions rises, there is a growing demand for effective biologic therapies that can provide long-lasting relief and improved quality of life for patients. Additionally, advancements in drug development and the continuous expansion of indications for etanercept enhance its therapeutic applications, further driving sales. The rising awareness among healthcare professionals and patients about the benefits of early treatment also contributes to the growing adoption of etanercept in clinical practice.
Restraints in the Global Etanercept Market
A significant market restraint for the global Etanercept market is the increasing prevalence of biosimilars. As the patent protection for Etanercept expires, several biosimilar versions are entering the market, leading to heightened competition and potential price erosion. This shift not only encourages cost-sensitive healthcare providers and patients to opt for these more affordable alternatives but also places pressure on original manufacturers to justify their pricing strategies. Additionally, the growing emphasis on value-based care and reimbursement models can further limit the adoption of Etanercept, as payers increasingly favor less expensive treatment options over branded therapies.
Market Trends of the Global Etanercept Market
The Global Etanercept market is experiencing a notable shift towards patient-centric care integration, emphasizing the customization of drug administration tailored to individual patient needs. This trend is characterized by flexible scheduling of doses, enhanced support programs, and educational initiatives that foster patient engagement and treatment adherence. By prioritizing holistic therapeutic outcomes, the market is differentiating itself through added value beyond mere efficacy, focusing on comprehensive treatment experiences that resonate with patients. Such advancements not only improve health outcomes but also cultivate stronger brand loyalty, positioning Etanercept favorably against competitors that may lack similar support infrastructures.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Etanercept Market Size by Product Drug Type & CAGR (2026-2033)
- Market Overview
- Originator Biologics
- Biosimilars
- Benepali
- Erelzi
- Nepexto
- Others
Global Etanercept Market Size by Application Clinical Indication & CAGR (2026-2033)
- Market Overview
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Plaque Psoriasis
- Juvenile Idiopathic Arthritis
Global Etanercept Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Subcutaneous Injections
- Intravenous Infusions
Global Etanercept Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Etanercept Market Size & CAGR (2026-2033)
- North America (Product Drug Type, Application Clinical Indication, Route of Administration, Distribution Channel)
- US
- Canada
- Europe (Product Drug Type, Application Clinical Indication, Route of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Product Drug Type, Application Clinical Indication, Route of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Product Drug Type, Application Clinical Indication, Route of Administration, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Product Drug Type, Application Clinical Indication, Route of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Amgen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Samsung Bioepis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Celltrion Healthcare
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aurobindo Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Lifesciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hikma Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alkem Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Torrent Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biogen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fresenius SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Coherus BioSciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
